Company / R&D Expense
Incyte R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.1B
FY2025
5-year range
$1.5B / $2.6B
FY2021-FY2025
Trend
-21.4%
vs FY2024
Sector context
#12 of 210
Health Care
What the data says
Among 210 Health Care companies, Incyte is in the top 6% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $582M in FY2016 to $2.6B in FY2024.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +11.3%. Top quartile in the Health Care sector.
Improved from $1.6B to $2.1B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- +11.3%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 210This company $2.1B Sector average $644.1M
▼
+218.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +11.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 21.4% year-over-year.
- Ranks #12 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | -21.4% |
| FY2024 | $2.6B | +60.2% |
| FY2023 | $1.6B | +2.6% |
| FY2022 | $1.6B | +8.8% |
| FY2021 | $1.5B | +21.7% |
| FY2020 | $1.2B | -9.7% |
| FY2019 | $1.3B | +10.7% |
| FY2018 | $1.2B | -9.7% |
| FY2017 | $1.3B | +127.9% |
| FY2016 | $581.9M | +21.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026